Tejara Capital Ltd Buys 511,992 Shares of Maravai LifeSciences Holdings, Inc. $MRVI

Tejara Capital Ltd increased its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 26.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,453,441 shares of the company’s stock after purchasing an additional 511,992 shares during the period. Maravai LifeSciences makes up 3.7% of Tejara Capital Ltd’s holdings, making the stock its 8th largest position. Tejara Capital Ltd’s holdings in Maravai LifeSciences were worth $7,041,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Ballentine Partners LLC acquired a new stake in shares of Maravai LifeSciences in the 3rd quarter valued at about $37,000. General American Investors Co. Inc. acquired a new stake in Maravai LifeSciences in the 3rd quarter valued at approximately $391,000. Y Intercept Hong Kong Ltd bought a new stake in Maravai LifeSciences in the 3rd quarter valued at approximately $97,000. Ethic Inc. boosted its position in Maravai LifeSciences by 62.8% during the 3rd quarter. Ethic Inc. now owns 16,951 shares of the company’s stock worth $49,000 after acquiring an additional 6,540 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Maravai LifeSciences by 141.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 18,757 shares of the company’s stock worth $54,000 after acquiring an additional 10,982 shares during the last quarter. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

NASDAQ:MRVI opened at $3.36 on Friday. The stock has a market capitalization of $859.19 million, a PE ratio of -4.00 and a beta of 0.33. Maravai LifeSciences Holdings, Inc. has a 1-year low of $1.66 and a 1-year high of $5.19. The firm has a fifty day simple moving average of $3.62 and a 200 day simple moving average of $3.10. The company has a current ratio of 5.29, a quick ratio of 4.56 and a debt-to-equity ratio of 0.74.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The firm had revenue of $41.63 million during the quarter, compared to analyst estimates of $49.02 million. On average, research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Wells Fargo & Company lifted their price target on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, December 15th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences presently has an average rating of “Hold” and an average price target of $5.25.

Insider Activity

In other Maravai LifeSciences news, Director Gregory T. Lucier purchased 48,528 shares of Maravai LifeSciences stock in a transaction that occurred on Monday, December 8th. The stock was acquired at an average price of $3.67 per share, for a total transaction of $178,097.76. Following the completion of the acquisition, the director owned 155,123 shares of the company’s stock, valued at approximately $569,301.41. This trade represents a 45.53% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Bernd Brust purchased 216,212 shares of the stock in a transaction on Thursday, November 13th. The shares were acquired at an average cost of $3.25 per share, for a total transaction of $702,689.00. Following the transaction, the chief executive officer owned 466,771 shares of the company’s stock, valued at approximately $1,517,005.75. The trade was a 86.29% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 566,771 shares of company stock valued at $1,880,244 over the last quarter. 2.11% of the stock is currently owned by company insiders.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.